Biopharma News

Regeneron Pharmaceuticals has entered into a significant collaboration with Telix Pharmaceuticals, valued at up to $2.1 billion. This partnership aims to

Philips has achieved a significant milestone by obtaining 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Rembra scanning

Erasca is positioning itself as a potential heavyweight in the biotech industry, targeting the lucrative oncology sector with its innovative approach to

Recent developments in oncology drug development highlight both advancements and setbacks within the field. The landscape is continuously evolving, driven

Recent research highlights a significant gap in the utilization of next generation sequencing (NGS) for patients diagnosed with advanced cancer. A

The recent failure of a Phase 3 clinical trial has led Gilead Sciences and Arcus Biosciences to halt a mid stage study of their investigational TIGIT

Gilead Sciences’ recent agreement to acquire Tubulis GmbH for over $5 billion highlights the growing focus within the biotech industry on antibody drug

Understanding why certain tumor cells exhibit heightened aggression, invasiveness, and resistance to treatments poses a significant challenge in cancer

Recent advancements in the treatment of bowel cancer have introduced a groundbreaking immunotherapy regimen that significantly enhances survival rates for

The American Association for Cancer Research (AACR) convened in San Diego, California, from April 17 to 22, 2026, bringing together researchers and

Immunotherapy is reshaping the landscape of cancer treatment, particularly for patients battling bladder cancer. Recent research demonstrates that a

Recent developments in pancreatic cancer research reveal encouraging results from an innovative mRNA vaccine combined with immunotherapy. Early trial data

The field of CAR T cell therapy has made significant strides in treating certain blood cancers, but progress with solid tumors has been slower. A major

Chimeric antigen receptor T cell (CAR T) therapy has shown remarkable potential in treating high risk smoldering multiple myeloma (SMM), according to

The landscape of cancer treatment is rapidly evolving, particularly in the realm of T cell redirection therapies. These innovative approaches leverage the

In the realm of precision oncology, accurately characterizing protein variants is a critical challenge. Understanding how sequence alterations impact

Research into patient derived organoids (PDOs) and patient derived xenografts (PDXs) is emerging as a critical area in cancer biology. These innovative